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Abstract
Background: A thyroid stimulating hormone level is commonly measured in patients presenting
with symptoms of mania in order to rule out an underlying general medical condition such as
hyperthyroidism or thyrotoxicosis. Indeed, many cases have been reported in which a patient is
initially treated for bipolar mania, but is later found to have a thyroid condition. Several case reports
have noted the development of a thyroid condition in bipolar patients either on lithium
maintenance treatment or recently on lithium treatment.
Case presentation: We review a case in which a patient with a long history of bipolar disorder
presents with comorbid hyperthyroidism and bipolar mania after recent discontinuation of lithium
treatment.
Conclusion: Physicians should consider a comorbid hyperthyroidism in bipolar manic patients
only partially responsive to standard care treatment with a mood stabilizer and antipsychotic.
Background
Multiple cases of patients with thyrotoxicosis presenting
with symptoms clinically indistinguishable from bipolar
mania have been reported [1-8]. Moreover, lithium for the
management of preexisting bipolar disorder has many
known effects on thyroid function [1,2,4,6,8-10]. We
report the case of a patient whose chronic lithium was dis-
continued owing to other concerns and who then pre-
sented with manic and psychotic symptoms apparently
related to thyrotoxicosis.
Case presentation
Ms F is a 59-year-old female with a long history of bipolar
disorder, previously well controlled on a stable dose of
lithium carbonate, who presented for hospitalization
with an apparent manic episode. She reported four weeks
of decreased sleep, hypersexuality, mood lability,
increased spending, impulsive behavior and psychotic
symptoms. The patient and her sister both noted that the
symptoms were consistent with her manic episodes in the
remote past. Ms F reported a recent change in her medica-
tion from lithium carbonate to aripiprazole, made by a
new psychiatrist, who was uncomfortable with prescrib-
ing lithium after the patient had been hospitalized for
lithium toxicity a month prior to admission.
Her psychiatric history included multiple episodes of
mania with subsequent hospitalizations in the remote
past. Past medication trials included risperidone, aripipra-
zole, quetiapine, lithium carbonate and depakote. The
past medical history was significant for arthritis, hyperc-
holesterolemia, irritable bowel disorder and a history of
depressed thyroid-stimulating hormone (TSH), with nor-
mal free T4. On transfer from an outside psychiatric hos-
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simvastatin 40 mg daily, lithium citrate 300 mg twice
daily and aspirin 81 mg daily. On initial admission to the
outside psychiatric hospital, Ms F's medications were arip-
iprazole 15 mg at night, simvastatin 40 mg daily and aspi-
rin 81 mg daily.
Physical examination determined that she was overweight
with findings of 3+ deep tendon reflexes bilaterally, a fine
tremor noted in bilateral upper extremities, mild propto-
sis, a non-tender, non-palpable thyroid, non-pitting
edema in her lower extremities and dry skin.
Mental status examination determined that she was alert
and oriented ×4, fairly groomed in appropriate dress with
good eye contact, and polite and cooperative with the
interview and exam. Her speech was not pressured, loud
or rapid. She denied auditory and visual hallucinations,
suicidal ideation and homicidal ideation. However, she
did endorse paranoid ideation and delusions with racial
themes. Her thought processes were mostly linear, with
some circumstantiality, but no flight of ideas, no loose-
ness of associations or ideas of reference. Ms F's cognition
and memory were intact.
Her admission laboratory tests including complete blood
count, chemistry, liver function tests, rapid plasma reagin
(RPR) and urine drug screen were within normal limits,
with the exception of TSH level of less than 0.005 (0.60–
3.30 µIU) and free T4 level of 2.11 (0.71–1.40 ng/ml).
TSH and free T4 from an outside psychiatric hospital two
days prior to admission were 0.008 and 2.48, respectively.
Once admitted to an acute psychiatric unit, Ms F was con-
tinued on lithium 300 mg twice daily. Her dose was
increased to a total daily dose of 900 mg after a lithium
level of 0.4 mmol/l on hospital day 4. Risperidone 2 mg
nightly for the treatment of psychotic symptoms was
added to her quetiapine 25 mg nightly. Repeated physical
examinations showed return to normal deep tendon
reflexes and resolution of tremor by hospital day 5, but
her TSH level was still less than 0.005 on day 5 with a free
T4 level of 1.81. Owing to continued psychosis and
insomnia, on day 7 her risperidone was increased to 3 mg
nightly and zolpidem 10 mg nightly replaced the
quetipine. No changes were made to patient's lithium
dose after day 4 because her lithium level was stable at 0.9
units by day 8. On day 11 her TSH level remained at less
than 0.005, with a free T4 level of 1.57. On day 12 the ris-
peridone was increased to 3 mg nightly with 0.5 mg daily.
She had not returned to her baseline by day 12, despite a
therapeutic level of lithium and a moderate dose of risp-
eridone. On day 13, her zolpidem was discontinued and
quetiapine was restarted at 100 mg nightly for manage-
ment both of insomnia and psychotic symptoms. A free
T3 level of 4.4 (0.2–0.4 ng/dl) substantiated a diagnosis of
hyperthyroidism on day 13. Methimazole 10 mg nightly
was started, and the patient reported her first night of
good sleep.
According to Ms F and available collateral information,
her TSH level had been depressed for more than three
years, with a normal free T4 level. Consequently, she
remained untreated throughout that time, followed with
laboratory tests every six months. However, given the
patient's persistent symptoms of insomnia and psychosis,
despite adequate doses of risperidone and lithium, and
given her initial presentation with symptoms of clinical
hyperthyroidism including proptosis, a tremor and
increased deep tendon reflexes, there was a high index of
suspicion for thyrotoxicosis. Thus, the patient's TSH and
free T4 were followed throughout her hospitalization.
Treatment was withheld initially owing to potential
hypothyroidism secondary to restarting lithium. The
patient was ultimately started on methimazole for treat-
ment of hyperthyroidism, which was diagnosed after
serial TSH levels continued to be depressed, with an ele-
vated free T3 level measured on hospital day 13. Ms F
responded well to the start of methimazole, with rapid
resolution of insomnia and psychotic symptoms. Both the
patient and her family members noted a return to baseline
by hospital day 19, after six days of stable treatment on
methimazole, lithium, quetiapine and risperidone.
The patient's refractory symptoms suggest that patients
may in fact present with comorbid hyperthyroidism and
bipolar mania. Another interpretation of the patient's par-
tial response to therapeutic levels of lithium and adequate
doses of risperidone is that her hyperthyroidism had been
unmasked by the discontinuation of lithium, and that her
presentation was entirely the result of a rebound type reac-
tion [9]. In other words, the removal of lithium, an agent
known to suppress thyroid activity through several mech-
anisms, unveiled the patient's previously controlled
hyperthyroidism [3,9]. However, given the patient's his-
tory and family collateral confirming that her behavior
was consistent with manic episodes in the past, it is more
likely that the lithium served the dual purpose of thyroid
suppression and treatment of her bipolar disorder. Thus,
the patient's resulting mania after discontinuation of her
lithium was exacerbated by a concurrent hyperthyroid
state/silent thyroiditis.
Conclusion
We have reported a case in which a patient who was stable
on lithium for decades was taken off of it owing to toxicity
and then presented with manic and psychotic symptoms.
Several mechanisms have been described regarding how
lithium disrupts the hypothalamic-pituitary-thyroid axis,Page 2 of 3
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thus leading to thyroid dysfunction [1,2,4,6]. Transient
hypothyroidism has been observed in up to 30% of
patients treated with lithium [9]. A literature review by
Carmaciu et al [3] yielded 50 cases of lithium-associated
hyperthyroidism after a reduction or discontinuation of
lithium treatment. Although the majority of lithium-
treated patients that develop abnormal thyroid conditions
present with hypothyroidism, several cases of lithium-
associated thyrotoxicosis, from a silent thyroiditis to
Graves' disease, have been reported [9,11].
Lithium is a monovalent cation that becomes concen-
trated in the thyroid gland where it interferes with the
release of thyroid hormone in several ways [5]: inhibition
of adenylate cyclase stimulated by TSH in normal
patients; decreased thyroid iodine uptake; decreased
release of T4 and T3; decreased hepatic metabolism of T4
to T3; and increased intrathyroidal iodine stores through
iodine retention.
Carmaciu et al [3] further delineates five mechanisms in
which lithium is thought to mediate thyrotoxicosis in
some patients that have been on maintenance treatment:
(1) lithium triggered autoimmune process with resultant
anti-thyroid antibodies; (2) abnormal iodine kinetics,
that is, overflow of thyroid hormone after expansion of
the intrathyroid iodine pool; (3) Jod-Basedow-like phe-
nomenon; (4) direct toxicity to thyroid follicules, result-
ing in release of thyroglobulin; and (5) coincidental
Graves' disease and hyperthyroidism.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
Both authors have read and approved the final manu-
script. CSNL was the primary provider for the patient
described in above, and wrote the initial draft of the
report. BH reviewed and supervised the writing of the
case.
Acknowledgements
Dr Stephen Ford, Dorthea Dix Hospital, Raleigh, North Carolina served as 
the attending supervisor for the case.
References
1. Baethge C, Blumentritt H, Berghofer A, Bschor T, Glenn T, Adli M,
Schlattmann P, Bauer M, Finke R: Long-term lithium treatment
and thyroid antibodies: a controlled study.  J Psychiatry Neurosci
2005, 30:423-427.
2. Becerra-Fernandez : Autoimmune thyrotoxicosis during lith-
ium therapy in a patient with manic-depressive illness.  Am J
Med 1995, 99:575.
3. Carmaciu CD, Anderson CS, Lawton CA: Case report: thyrotox-
icosis after complete or partial lithium withdrawal in two
patients with bipolar affective disorder.  Bipolar Disord 2003,
5:381-384.
4. Cassidy F, Ahearn EP, Carroll BJ: Thyroid function in mixed and
pure manic episodes.  Bipolar Disord 2002, 4:393-397.
5. McDermott MT, Burman KD, Hofeldt FD, Kidd GS: Lithium-asso-
ciated thyrotoxicosis.  Am J Med 1986, 80:1245-1248.
6. Moniwa E, Lee TW, Lofchy J: Letters to the editor: revisiting the
diagnostic challenges of secondary mania and bipolar disor-
der in a patient with borderline hyperthyroidism.  Can J Psychi-
atry 2004, 49:685-686.
7. North J, Sagar R: Late-onset bipolar disorder due to hyperthy-
roidism.  Acta Psychiatr Scand 2001, 104:72-75.
8. Parker PE, Walter-Ryan WG, Pittman CS, Folks DG: Lithium treat-
ment of hyperthyroidism and mania.  J Clin Psychiatry 1986,
47:264-266.
9. Daniels G, Miller K: Association between lithium use and thy-
rotoxicosis caused by silent thyroiditis.  Clin Endocrinol (Oxf)
2001, 55:501-508.
10. Thomsen AF, Kessing LV: Increased risk of hyperthyroidism
among patients hospitalized with bipolar disorder.  Bipolar Dis-
ord 2005, 7:351-357.
11. Schoenberg M, Ts'o TO, Meisel AN: Graves' disease manifesting
after maintenance lithium.  J Nerv Ment Dis 1979, 167:575-577.Page 3 of 3
(page number not for citation purposes)
